M
Megan R. Lerner
Researcher at University of Oklahoma Health Sciences Center
Publications - 133
Citations - 4624
Megan R. Lerner is an academic researcher from University of Oklahoma Health Sciences Center. The author has contributed to research in topics: Cancer & Pancreatic cancer. The author has an hindex of 32, co-authored 132 publications receiving 4342 citations. Previous affiliations of Megan R. Lerner include Veterans Health Administration & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Expression profiling identifies microRNA signature in pancreatic cancer
Eun Joo Lee,Yuriy Gusev,Jinmai Jiang,Gerard J. Nuovo,Megan R. Lerner,Megan R. Lerner,Wendy L. Frankel,Daniel L. Morgan,Russell G. Postier,Daniel J. Brackett,Daniel J. Brackett,Thomas D. Schmittgen +11 more
TL;DR: A microRNA expression signature has been identified that is associated with pancreatic cancer and Aberrant microRNAs may offer new clues to pancreatic tumorigenesis and may provide diagnostic biomarkers for pancreatic adenocarcinoma.
Journal ArticleDOI
Mesothelin Is Overexpressed in Pancreaticobiliary Adenocarcinomas but Not in Normal Pancreas and Chronic Pancreatitis
Raffit Hassan,Zoltan Laszik,Megan R. Lerner,Megan R. Lerner,Mark Raffeld,Russell G. Postier,Daniel J. Brackett,Daniel J. Brackett +7 more
TL;DR: The results demonstrated mesothelin expression in the majority of pancreaticobiliary adenocarcinomas and no expression in normal pancreatic tissues and in chronic pancreatitis.
Journal ArticleDOI
DCAMKL-1 regulates epithelial-mesenchymal transition in human pancreatic cells through a miR-200a-dependent mechanism
Sripathi M. Sureban,Randal May,Stan Lightfoot,Aimee B. Hoskins,Megan R. Lerner,Daniel J. Brackett,Russell G. Postier,Rama P. Ramanujam,Altaf Mohammed,Chinthalapally V. Rao,James H. Wyche,Shrikant Anant,Courtney W. Houchen +12 more
TL;DR: Increased expression of the putative pancreatic stem cell marker DCAMKL-1 is reported in an established KRAS transgenic mouse model of pancreatic cancer and in human pancreatic adenocarcinoma, and a functional role is demonstrated for DCAMC-1 in Pancreatic cancer.
Journal ArticleDOI
miR-132 and miR-212 are increased in pancreatic cancer and target the retinoblastoma tumor suppressor
Jong Kook Park,Jon C. Henry,Jinmai Jiang,Christine Esau,Yuriy Gusev,Megan R. Lerner,Russell G. Postier,Daniel J. Brackett,Thomas D. Schmittgen +8 more
TL;DR: It is reported that over-expression of miR-132 andMiR-212 result in reduced pRb protein in pancreatic cancer cells and that the increase in cell proliferation from over- expression of these miRNAs is likely due to increased expression of several E2F target genes.
Journal ArticleDOI
σ Receptors: potential medications development target for anti-cocaine agents
TL;DR: The ability of cocaine to interact with sigma receptors suggests a viable target for medications development and promising future directions for the development of potential medications for the treatment of cocaine addiction and overdose are provided.